Opinion: Takeaways from a biotech CEO on the House’s passage of H.R. 3
The word "negotiate" in H.R. 3 is semantic trickery: The bill authorizes the federal government to impose a staggering 95% excise tax on drug makers who don't sell at prices…
While the big party-line vote in the House of Representatives last week about articles of impeachment and the state of our union captured America’s attention, another near-party-line vote in the chamber on Speaker Nancy Pelosi’s legislation to impose European-style price controls on the most innovative drugs offered important lessons about the state of U.S. drug policy.
, also known as the Elijah E. Cummings Lower Drug Costs Now Act, passed on a vote of 230-192. The bill seeks to expand on President Donald Trump’s more limited foreign reference pricing proposal by authorizing the government to “negotiate” dramatically lower prices for 250 different drugs in Medicare and then apply those negotiated prices
